• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Read More
Dave Lennon, PhD
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Mohammad Hirmand, MD
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Read More
Richard Maroun, JD
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Comments

Comments are closed.

  • Next Post
  • Previous Post